CorMedix CLO uses 8.4K shares for award costs

Rhea-AI Filing Summary

CorMedix Inc. (CRMD) reported that Chief Legal Officer Beth Zelnick Kaufman had 8,424 shares of common stock disposed of on 2026-08-29 in a transaction coded "F," representing payment of exercise price or tax liability by delivering or withholding securities. Following this withholding transaction, she directly holds 260,684 shares of CorMedix common stock.

Insider Trade Summary

Net Seller: 8,424 shares

Net Sell 1 txn

Insider Zelnick Kaufman Beth

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	8,424	$8.30	$70K

Holdings After Transaction: Common Stock — 260,684 shares (Direct)

Key Figures

Shares disposed (code F): 8,424 shares of Common Stock Transaction price per share: $8.30 per share Shares owned after transaction: 260,684 shares of Common Stock

3 metrics

Shares disposed (code F) 8,424 shares of Common Stock Payment of exercise price or tax liability by delivering or withholding securities on 2026-08-29

Transaction price per share $8.30 per share Applied to 8,424-share code F disposition

Shares owned after transaction 260,684 shares of Common Stock Direct holdings of Beth Zelnick Kaufman following the 2026-08-29 transaction

Key Terms

Common Stock, Payment of exercise price or tax liability, withholding securities

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Payment of exercise price or tax liability financial

"transaction_code_description: "Payment of exercise price or tax liability""

withholding securities financial

"transaction_code_description: "by delivering or withholding securities""

FAQ

What insider transaction did CRMD report for Beth Zelnick Kaufman?

CorMedix reported that Beth Zelnick Kaufman had 8,424 shares of common stock disposed of on 2026-08-29 in a code "F" transaction, meaning shares were delivered or withheld to pay exercise price or tax liability, leaving her with 260,684 shares directly held.

How many CRMD shares does Beth Zelnick Kaufman hold after this Form 4 transaction?

After the reported transaction, Beth Zelnick Kaufman directly holds 260,684 shares of CorMedix Inc. common stock. This figure reflects her holdings immediately following the 8,424-share code "F" disposition on 2026-08-29.

What does the code "F" mean in the CRMD Form 4 for Beth Zelnick Kaufman?

In this Form 4, transaction code "F" is described as "Payment of exercise price or tax liability by delivering or withholding securities". It indicates shares were used to satisfy costs related to an equity award rather than an open-market sale.

At what price per share were the 8,424 CRMD shares valued in this Form 4?

The 8,424 shares involved in the code "F" transaction were valued at $8.30 per share. The filing characterizes this as a per-share figure associated with the payment of exercise price or tax liability by delivering or withholding securities.

Was the CRMD insider transaction reported as a buy or a sell?

The transaction is categorized as a disposition related to payment of exercise price or tax liability. It is not reported as a traditional market purchase or sale but as shares delivered or withheld to cover equity-award-related costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 08:17 PM Accepted by SEC EDGAR 09/01/2026 - 08:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zelnick Kaufman Beth

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NEW JERSEY 07054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2026		F		8,424	D	$8.3	260,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Beth Zelnick Kaufman	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)